ABSTRACT
Background and Objectives. The aim of this study is to compare clinical and epidemiological characteristics and outcomes in patients with versus without nosocomial COVID-19 after exposure to SARS-CoV-2 and to analyze the risk factors for severe outcomes of COVID-19 in a long-term hospital in Spain. Materials and methods. This retrospective, single-center observational study included all inpatients in a long-term hospital during a COVID-19 outbreak from 21 January to 15 March 2021. Results. Of 108 admitted patients, 65 (60.2%) were diagnosed with nosocomial COVID-19 disease (n = 34 women (52.3%), median age 77 years). In the univariable analysis, risk factors associated with nosocomial COVID-19 were dementia (OR 4.98 95% CI 1.58-15.75), dyspnea (OR 5.34 95% CI 1.69-16.82), asthenia (OR 5.10, 95% CI 1.40-18.60) and NECesidades PALiativas (NECPAL) (OR 1.28 95% CI 1.10-1.48). In the multivariable analysis, risk factors independently associated with nosocomial COVID-19 infection were dyspnea (aOR 7.39; 95% CI 1.27-43.11) and NECPAL (aOR 1.25; 95% CI 1.03-1.52). Of the 65 patients diagnosed with nosocomial COVID-19, 29 (44.6%) died, compared to 7/43 (16.2%) non-infected patients (OR 4.14, 95% CI 1.61-10.67). Factors associated with mortality in nosocomial COVID-19 were confusion (aOR 3.83; 95% CI 1.03-14.27) and dyspnea (aOR 7.47; 95% CI 1.87-29.82). The NECPAL tool played an important predictive role in both nosocomial COVID-19 infection and mortality (aOR 1.19, 95% CI: 1.00-1.41). Conclusions. In a long-term hospital, nosocomial COVID-19 main clinical characteristics associated with infection were dyspnea and NECPAL. Mortality was higher in the group with nosocomial COVID-19; risk factors were confusion and dyspnea. The NECPAL tool may help to predict progression and death in COVID-19.
Subject(s)
COVID-19 , Cross Infection , Aged , Cross Infection/epidemiology , Dyspnea/etiology , Female , Hospitals , Humans , Retrospective Studies , SARS-CoV-2 , Spain/epidemiologyABSTRACT
No disponible
Subject(s)
Humans , Basophils , Asthma/blood , Biomarkers/blood , Omalizumab/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapyABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Interferon-beta/administration & dosage , Sarcoidosis/chemically induced , Interferon-beta/adverse effects , Sarcoidosis/blood , Sarcoidosis/drug therapy , BronchoscopySubject(s)
Interferon beta-1a/adverse effects , Sarcoidosis/chemically induced , Anti-Inflammatory Agents/therapeutic use , Erythema Nodosum/etiology , Female , Humans , Immunosuppressive Agents/therapeutic use , Interferon beta-1a/pharmacology , Interferon beta-1a/therapeutic use , Middle Aged , Multiple Sclerosis/drug therapy , Prednisone/therapeutic use , Sarcoidosis/drug therapy , Sarcoidosis/immunology , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunologyABSTRACT
No disponible